Question · asked by 1 review
Thalidomide (systemic; 100 mg or 300 mg daily) vs placebo: Number of (minor aphthous) oral ulcers
- Population
- People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
- Intervention
- Thalidomide (systemic; 100 mg or 300 mg daily)
- Comparison
- placebo
- Outcome
- Number of (minor aphthous) oral ulcers
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Thalidomide (systemic; 100 mg or 300 mg daily) vs Placebo Number of (minor aphthous) oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… · Males only Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane All outcomes | Hamuryudan 1998 (thalidomide 100 mg or 300 mg daily vs placebo, 101 male patients; high risk of reporting bias): a significant effect on mean numbers of minor oral ulcers was reported from week 4 in both thalidomide… | 1 study · 101 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes | 2013-10 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.